Publications by authors named "Paola Degregorio"
Article Synopsis
- Advanced practice providers (APPs) are crucial in detecting and managing adverse reactions (ARs) associated with lenvatinib, especially since these ARs can mimic cirrhosis linked to hepatocellular carcinoma (HCC).
- The post-hoc analysis of the REFLECT trial aimed to identify and discuss management strategies for key ARs related to lenvatinib treatment in patients with unresectable HCC.
- Key ARs typically presented within months of treatment initiation, and while they can often be managed by adjusting the dosage or withholding the drug, lenvatinib should be discontinued if a reaction is life-threatening.
Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas. The GFP regimen (gemcitabine, 5-fluorouracil, leucovorin, and cisplatin) is based on laboratory evidence of disease-specific chemotherapy interaction. This retrospective analysis examined the outcome of 49 consecutive patients with histologically confirmed metastatic pancreatic adenocarcinoma treated between July 1998 and September 2000.
View Article and Find Full Text PDF